???global.info.a_carregar???
Sara M Lopes (PharmD, PhD) is a junior researcher at the Gene and Stem Cell Therapies for the Brain Group at the Center for Neuroscience and Cell Biology (CNC), University of Coimbra. She got her PhD in 2021, where she acquired a vast experience on the design and construction of sequence-specific nucleases (with expertise in TALENs and CRISPR systems), viral vectors for therapy (lentivirus and adeno-associated virus) and pre-clinical models of the disease. Sara is the author of 9 peer-reviewed articles in scientific journals, 2 book chapters and of 2 provisional patent applications. She has an active participation in both national and international scientific meetings, being the author of a total of 38 oral communications and 51 poster presentations. The work that she has developed was awarded twice with the Best Work in Basic Research, attributed by the Portuguese Society of Movement Disorders in 2018 and by the Portuguese Society of Human Genetics in 2020. More recently she participated in entrepreneurship programmes, having received the bronze award (10.000€) from the EIT health DPhil PhD transition Fellowship for the project ExoEditor (2017) and the first prize (20.000€) of the innovation programme in neuroscience (Building Tomorrow Together) for the project ExoTreat, an initiative from Roche (2020).
Ler resumo completo ↓
Identificação

Identificação pessoal

Nome completo
Sara Isabel Monteiro Lopes

Nomes de citação

  • Lopes, Sara M.
  • Sara M. Lopes
  • Lopes, Sara
  • Sara Lopes
  • Lopes, S. M.
  • S. M. Lopes

Identificadores de autor

Ciência ID
D715-EE08-5DD9
ORCID iD
0000-0002-4322-8529

Domínios de atuação

  • Ciências Médicas e da Saúde - Medicina Básica - Farmacologia e Farmácia
  • Ciências Médicas e da Saúde - Biotecnologia Médica - Biotecnologia Aplicada à Saúde
  • Ciências Médicas e da Saúde - Biotecnologia Médica - Tecnologias que envolvem a Manipulação de Células,Tecidos,Órgãos ou todo o Organismo
  • Ciências Médicas e da Saúde - Biotecnologia Médica - Diagnóstico e Terapias de Base Genética
  • Ciências Médicas e da Saúde - Medicina Básica - Neurociências
  • Ciências Médicas e da Saúde - Medicina Básica - Genética Humana
  • Ciências Naturais - Ciências Biológicas - Biologia Celular
  • Ciências Naturais - Ciências Biológicas - Biologia Molecular
  • Ciências Naturais - Ciências Biológicas - Microbiologia

Idiomas

Idioma Conversação Leitura Escrita Compreensão Peer-review
Português (Idioma materno)
Inglês Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2)
Espanhol; Castelhano Utilizador independente (B2) Utilizador proficiente (C1) Utilizador independente (B2) Utilizador proficiente (C1)
Francês Utilizador elementar (A1) Utilizador independente (B1) Utilizador elementar (A1) Utilizador elementar (A2)
Formação
Grau Classificação
2021/10/21
Concluído
 Doutoramento em Biologia Experimental e Biomedicina (Doutoramento)
Especialização em Biotecnologia e Saúde
Universidade de Coimbra Instituto de Investigação Interdisciplinar, Portugal

Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
"Gene editing technologies to Machado-Joseph disease" (TESE/DISSERTAÇÃO)
 Louvor e distinção por unanimidade
2019
Concluído
 CERTIFICATION: Investigator authorized to perform animal procedures (small rodents), in accordance with Portuguese national regulations on animal experimentation (Outros)
Direcção Geral de Veterinária, Portugal
2010/09/24
Concluído
 Mestrado Integrado em Ciências Farmacêuticas (Mestrado integrado)
Universidade de Coimbra Faculdade de Farmácia, Portugal
"Antidepressivos e Neurogénese" (TESE/DISSERTAÇÃO)
 15
Percurso profissional

Ciência

Categoria Profissional
Instituição de acolhimento 		Empregador
2023/06 - Atual Investigador Contratado (Investigação) Universidade de Coimbra, Portugal
Universidade de Coimbra Centro de Inovação em Biomedicina e Biotecnologia, Portugal
(...)
2022/01/01 - 2023/04 Pós-doutorado (Investigação) Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
2015/10/01 - 2021/12/31 Investigador (Investigação) Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
Vectors and Gene Therapy Group, Center for Neuroscience and Cell Biology, University of Coimbra, Portugal
2010/09/01 - 2011/08/31 Investigador (Investigação) Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
Redox Biology and Brain Sensing Group, Center for Neuroscience and Cell Biology, University of Coimbra, Portugal
2009/10 - 2010/01 Estagiário de Investigação (Investigação) Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
Neuroendocrinology and Ageing group, Center for Neuroscience and Cell Biology, University of Coimbra, Portugal

Docência no Ensino Superior

Categoria Profissional
Instituição de acolhimento 		Empregador
2024/09/01 - 2025/08/31 Professor Auxiliar Convidado (Docente Universitário) Universidade de Coimbra Faculdade de Farmácia, Portugal
2022/04/01 - 2022/08/31 Professor Auxiliar Convidado (Docente Universitário) Universidade de Coimbra Faculdade de Farmácia, Portugal

Outros

Categoria Profissional
Instituição de acolhimento 		Empregador
2012/10/18 - 2012/11/19 Graduate Student Researcher Broad Institute, Estados Unidos
Projetos

Bolsa

Designação Financiadores
2024/01/01 - Atual GeneT - The Gene Therapy CoE at the Center of Portugal
101059981
Investigador
European Union
Em curso
2024 - Atual ERDERA - European Rare Diseases Research Alliance
101156595
Investigador
European Union
Em curso
2023/09/01 - 2026/08/31 NEURODIET - Molecular Mechanisms of Dietary Intervention on Neurodegeneration (PT001)
JPND/0001/2022
10.54499/JPND/0001/2022
Investigador
Universidade de Coimbra, Portugal

Universidade de Coimbra Centro de Inovação em Biomedicina e Biotecnologia, Portugal

Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
Fundação para a Ciência e a Tecnologia
Em curso
2023/03/01 - 2024/08/31 From “bedside-to-bench” biomarker discovery: on the road to a clinical trial for Machado-Joseph Disease
2022.06118.PTDC
Investigador
Universidade de Coimbra, Portugal
 Fundação para a Ciência e a Tecnologia
Em curso
2022/01/01 - 2023/06/30 Genome editing to rescue Machado-Joseph disease by alternative splicing
EXPL/MED-NEU/0936/2021
Investigador
Universidade de Coimbra, Portugal

Universidade de Coimbra Instituto de Investigação Clínica e Biomédica de Coimbra, Portugal
Fundação para a Ciência e a Tecnologia
Concluído
2022/11/01 - 2023/06/29 Fighting Sars-CoV-2 with viral vectors
CENTRO-01-01D2-FEDER000002
Bolseiro de Pós-Doutoramento
Universidade de Coimbra Centro de Inovação em Biomedicina e Biotecnologia, Portugal

Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal

Universidade de Coimbra, Portugal
Universidade de Coimbra
Concluído
2019/11/18 - 2021/12/31 BrainHealth 2020: Detecção precoce, neuro-modulação e terapias avançadas para neuropatologias
CENTRO-01-0145-FEDER-000008
Bolseiro de Investigação
CNC.IBILI, Portugal
 Centro 2020 (Programa Operacional da Região Centro)
Concluído
2010/09/01 - 2011/08/31 In vivo dynamics of nitric oxide in the brain: regulation of cellular respiration and implications for Alzheimer´s disease and aging
PTDC/SAU-NEU/103538/2008
Bolseiro de Investigação
Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
 Associação para a Inovação e Desenvolvimento da FCT
Concluído

Projeto

Designação Financiadores
2023/06/30 - Atual CiNTech - Technological Hub for Innovation, Translation and Industrialization of Complex Injectable Drugs
C644865576-00000005
Investigador
Universidade de Coimbra Centro de Inovação em Biomedicina e Biotecnologia, Portugal

Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal

Universidade de Coimbra, Portugal
Universidade de Coimbra
Em curso
2019 - Atual Targeting mutant ATXN3 for the treatment of Spinocerebellar Ataxia 3 (SCA3) using allele-specific ASOs
N.A
Investigador
Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
 Wave Life Sciences
Em curso
2022/01 - 2022/10 Collaboration agreement - F. Hoffmann - La Roche Ltd (Roche Group)
n.a
Bolseiro de Pós-Doutoramento
Universidade de Coimbra Centro de Inovação em Biomedicina e Biotecnologia, Portugal

Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
F Hoffmann-La Roche AG

F Hoffmann-La Roche AG Research and Development Division
2015/01/01 - 2019/12/31 CNC.IBILI
UID/NEU/04539/2013
UID/NEU/04539/2019
Investigador
CNC.IBILI, Portugal
 Associação para a Inovação e Desenvolvimento da FCT
Concluído
2017/08/01 - 2019/09/30 CutCAGs: Gene repair and repression strategies to alleviate Machado-Joseph disease
PTDC/NEU-NMC/0084/2014
POCI-01-0145-FEDER-016719
Bolseiro de Investigação
Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
 Associação para a Inovação e Desenvolvimento da FCT
Concluído
2016/10/01 - 2017/06/30 Research in stem cells and Machado Joseph disease
DPA-56-16-388
Bolseiro de Investigação
Universidade de Coimbra, Portugal

Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
Concluído
2016/04/15 - 2016/09/15 Towards the understanding of pathological protein processing and toxicity in Machado-Joseph Disease
E-Rare4/0003/2012
Bolseiro de Investigação
Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
Concluído
2015/10/01 - 2015/12/31 Cabaletta@CNC
n.a.
Bolseiro de Investigação
Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
 BioBlast Pharma, Ltda
Concluído
2011/10/01 - 2015/09/30 Gene Editing Technologies to Machado-Joseph Disease
SFRH/BD/51673/2011
Bolseiro de Doutoramento
Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
 Associação para a Inovação e Desenvolvimento da FCT
Concluído
2013 - 2014 Strategic Project - LA 1 - 2013-2014
PEst-C/SAU/LA0001/2013
Investigador
Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
 Associação para a Inovação e Desenvolvimento da FCT
Concluído
2011 - 2012 Strategic project - LA 1 - 2011-2012
PEst-C/SAU/LA0001/2011
Investigador
Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
 Associação para a Inovação e Desenvolvimento da FCT
Concluído
Produções

Publicações

Artigo em jornal
  1. João Ramalho-Santos; Sara Varela Amaral; Marta Quatorze; João Cardoso; Luís Pereira de Almeida; André Caetano; Ana Catarina Vinhas; et al. "Uma Viagem Rara", Público, 2020, https://www.publico.pt/2020/02/28/ciencia/fotogaleria/viagem-rara-400481.
Artigo em revista
  1. Elter, Tim Lukas; Sturm, Daniel; Santana, Magda M.; Schaprian, Tamara; Raposo, Mafalda; Melo, Ana Rosa Vieira; Lima, Manuela; et al. "Regional distribution of polymorphisms associated to the disease-causing gene of spinocerebellar ataxia type 3". Journal of Neurology 272 1 (2024): https://doi.org/10.1007/s00415-024-12829-9.
    Publicado • 10.1007/s00415-024-12829-9
  2. Leandro, Kevin; Rufino-Ramos, David; Breyne, Koen; Di Ianni, Emilio; Lopes, Sara M.; Jorge Nobre, Rui; Kleinstiver, Benjamin P.; et al. "Exploring the potential of cell-derived vesicles for transient delivery of gene editing payloads". Advanced Drug Delivery Reviews 211 (2024): 115346. https://doi.org/10.1016/j.addr.2024.115346.
    Publicado • 10.1016/j.addr.2024.115346
  3. Miguel M. Lopes; Lopes, Sara M. ; Rafael Baganha; Carina Henriques; Ana C. Silva; Diana D. Lobo; Luísa Cortes; Luís Pereira de Almeida; Rui Jorge Nobre. "Isolation of Adeno-associated Viral Vectors Through a Single-step and Semi-automated Heparin Affinity Chromatography Protocol". Journal of Visualized Experiments (JoVE) 206 (2024): e66550.
    Publicado
  4. Miguel M. Lopes; Jacques Paysan; José Rino; Sara M. Lopes; Pereira de Almeida, Luis ; Luísa Cortes; Rui Jorge Nobre. "A new protocol for whole-brain biodistribution analysis of AAVs by tissue clearing, light-sheet microscopy and semi-automated spatial quantification". Gene Therapy (2022): https://doi.org/10.1038/s41434-022-00372-z.
    10.1038/s41434-022-00372-z
  5. Vasconcelos-Ferreira, Ana; Martins, Inês Morgado; Lobo, Diana; Pereira, Dina; Miguel M. Lopes; Faro, Rosário; Lopes, Sara M. ; et al. "ULK overexpression mitigates motor deficits and neuropathology in mouse models of Machado-Joseph disease". Molecular Therapy 30 1 (2022): 370-387. http://dx.doi.org/10.1016/j.ymthe.2021.07.012.
    Publicado • 10.1016/j.ymthe.2021.07.012
  6. Nobre, Rui Jorge; Lobo, Diana D.; Henriques, Carina; Duarte, Sonia P.; Lopes, Sara M. ; Silva, Ana C.; Miguel M. Lopes; et al. "MiRNA-Mediated Knockdown of ATXN3 Alleviates Molecular Disease Hallmarks in a Mouse Model for Spinocerebellar Ataxia Type 3". Nucleic Acid Therapeutics (2021): http://dx.doi.org/10.1089/nat.2021.0020.
    Publicado • 10.1089/nat.2021.0020
  7. Lopes, Sara Monteiro; Faro, Rosário; Miguel M. Lopes; Onofre, Isabel; Mendonça, Nuno; Ribeiro, Joana; Januário, Cristina; Nobre, Rui Jorge; Pereira de Almeida, Luis. "Protocol for the Characterization of the CAG Tract and Flanking Polymorphisms in Machado-Joseph Disease: Impact on Diagnosis and Development of Gene-Based Therapies". The Journal of Molecular Diagnostics (2020): http://dx.doi.org/10.1016/j.jmoldx.2020.03.003.
    10.1016/j.jmoldx.2020.03.003
  8. Silva, Ana C; Lobo, Diana D; Martins, Inês M; Lopes, Sara Monteiro; Henriques, Carina; Duarte, Sónia P; Dodart, Jean-Cosme; Nobre, Rui Jorge; Pereira de Almeida, Luis. "Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders". Brain 143 2 (2020): 407-429. http://dx.doi.org/10.1093/brain/awz328.
    Publicado • 10.1093/brain/awz328
  9. Onofre, Isabel; Mendonça, Nuno; Lopes, Sara; Nobre, Rui; de Melo, Joana Barbosa; Carreira, Isabel Marques; Januário, Cristina; Gonçalves, António Freire; Pereira de Almeida, Luis. "Fibroblasts of Machado Joseph Disease patients reveal autophagy impairment". Scientific Reports 6 1 (2016): 28220. http://dx.doi.org/10.1038/srep28220.
    Publicado • 10.1038/srep28220
Capítulo de livro
  1. Lopes, Sara Monteiro; Pereira de Almeida, Luis. "Gene editing and central nervous system regeneration". In Handbook of Innovations in Central Nervous System Regenerative Medicine, editado por Antonio J. Salgado, 399-433. Elsevier, 2020.
    Publicado • 10.1016/b978-0-12-818084-6.00011-8
  2. Matos, Carlos A.; Carmona, Vítor; Vijayakumar, Udaya-Geetha; Lopes, Sara; Albuquerque, Patrícia; Conceição, Mariana; Nobre, Rui Jorge; Nóbrega, Clévio; Pereira de Almeida, Luis. "Gene Therapies for Polyglutamine Diseases". In Polyglutamine Disorders, editado por Nóbrega, Clévio; de Almeida, Luís Pereira, 395-438. Springer International Publishing, 2018.
    Publicado • 10.1007/978-3-319-71779-1_20
Poster em conferência
  1. Lopes, Sara M. ; Miguel M. Lopes; Ana Daniela Oliveira; Magda M. Santana; Ana R. Fernandes; Ana Vasconcelos-Ferreira; Pereira, Dina; et al. "Therapeutic Potential of CRISPR-Cas9-Mediated ATXN3 Gene Inactivation in Machado-Joseph Disease". Trabalho apresentado em Rare Disease Research Conference 2025, 2025.
  2. Rodrigo F.N. Ribeiro; Dina Pereira; Lopes, Sara M. ; Reis, Tiago; Silva, Patrick; Diana Lobo; Gaspar, Laetitia; et al. "Circadian rhythms are disrupted in Machado-Joseph Disease: an in vitro, in vivo, and clinical study". Trabalho apresentado em 2024 International Congress for Ataxia Research (ICAR2024), 2024.
  3. Pereira, Dina; Janete Cunha-Santos; Ana Vasconcelos-Ferreira; Joana Duarte-Neves; Isabel Onofre; Vítor Carmona; Célia A Aveleira; et al. Autor correspondente: Luís Pereira de Almeida. "Nuclear ageing in polyglutamine-induced neurodegeneration: a highlight on Machado-Joseph disease". Trabalho apresentado em International Congress for Ataxia Research 2024, 2024.
  4. Ana Rita Fernandes; Adão, Diana; Lopes, Sara M. ; Pena, Frederico; De Luca, Pasqualino; Henriques, Daniel; Mendonça, Liliana S.; et al. "Engineering of patient-derived isogenic neuronal models by CRISPR/Cas9 to unravel the impact of ATXN3 knockout in Spinocerebellar Ataxia Type 3". Trabalho apresentado em 2024 International Congress for Ataxia Research (ICAR2024), 2024.
  5. Serra, Beatriz; Sónia Duarte; João Almeida; Lopes, Sara M. ; Françoise Piguet; Nathalie Cartier; Sandro Alves; Pereira de Almeida, Luis Fernando Morgado; Rita Perfeito. "Validation of AAV-PHP.eB-mediated CYP46A1 systemic delivery: a promising non-invasive gene therapy for Spinocerebellar Ataxia Type 3". Trabalho apresentado em 2024 International Congress for Ataxia Research (ICAR2024), 2024.
  6. Maria Inês Barros; António Silva; Daniela Gonzaga; Diana Lobo; Pereira, Dina; Sónia Duarte; Lopes, Sara M. ; et al. "Mechanistic Insights into MSC Therapy for Machado-Joseph Disease: Nerve Growth Factor as a central effector?". Trabalho apresentado em 2024 International Congress for Ataxia Research (ICAR2024), 2024.
  7. Catarina Oliveira Miranda; Perfeito, Rita; Sónia P. Duarte; Paulo, Cristiana; RODRIGUES, MARIANA TEIXEIRA; Gaspar, Laetitia S; Pereira, Dina; et al. "Comparative analysis of transfection kits for linear, self-amplifying, and circular RNA". Trabalho apresentado em 31st Annual Congress of the European Society for Gene and Cell Therapy (ESGCT), 2024.
  8. Gaspar, Laetitia S; Marques, Bruno; Pereira, Dina; De Luca, Pasqualino; Pedro Perdigão; Lopes, Sara; Perfeito, Rita; et al. "Maximizing Yield and Functionality in saRNA Production: A Comparative Study of Commercial Kits and In Vitro Transcription Conditions". Trabalho apresentado em 31st Annual Congress of the European Society for Gene and Cell Therapy (ESGCT), 2024.
  9. De Luca, Pasqualino; Lopes, Sara; Pereira, Dina; Gaspar, Laetitia S; Marques, Bruno; Pedro Perdigão; Melo, Alexandra A.; et al. "Optimizing in vitro transcription methods for enhanced mRNA-based therapeutics". Trabalho apresentado em 31st Annual Congress of the European Society for Gene and Cell Therapy (ESGCT), 2024.
  10. Pereira, Dina; Valdeira, A. S. C.; Santos Silva, Francisca; Gaspar, Laetitia S; De Luca, Pasqualino; Pedro Perdigão; Lopes, Sara; et al. "A comparative analysis of commercial kits for enhanced circular mRNA production: yield, profile, and in vitro assessment". Trabalho apresentado em 31st Annual Congress of the European Society for Gene and Cell Therapy (ESGCT), 2024.
  11. Silva, Ana Carolina; Henriques, Carina; Lobo, Diana Duarte; Fernandes, Ana Rita; Lopes, M. M.; Leandro, Kevin; Pereira, Dina; et al. "Intra-cisterna magna administration of allele-specific AAV-based therapy alleviates neuropathology and motor deficits in spinocerebellar ataxia type 3". Trabalho apresentado em 31st Annual Congress of the European Society for Gene and Cell Therapy (ESGCT), 2024.
  12. Silva, Ana Carolina; Henriques, Carina; Lobo, Diana Duarte; Fernandes, Ana Rita; Lopes, M. M.; Pereira, Dina; Duarte, S.P.; et al. "Allele-specific silencing of mutant ATXN3 mitigates motor deficits and neuropathology in a severely impaired mouse model of spinocerebellar ataxia type 3 (SCA3)". Trabalho apresentado em 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), 2024.
  13. Lobo, Diana Duarte; Luís Quintino; Ana Carolina Silva; Carina Henriques; Ribeiro, Rodrigo; Lopes, Sara M. ; Pedro Perdigão; et al. Autor correspondente: Pereira de Almeida, Luis Fernando Morgado. "CRISPR activation as a therapeutic tool for Spinocerebellar ataxia type 3 (SCA3)". Trabalho apresentado em 30th Annual Meeting of the European Society of Gene & Cell Therapy (ESGCT), Brussels, Belgium, 2023.
  14. Barros, Inês; Gonzaga, Daniela; Lobo, Diana Duarte; Lopes, Sara; Martins, Inês; Silva, Ana Carolina; Pereira de Almeida, L; Miranda, Catarina. Autor correspondente: Miranda, Catarina. "The Guardians of Balance: Mesenchymal Stem Cells as a Promising Strategy to Restore Blood-brain Barrier Integrity in Spinocerebellar Ataxia Type 3.". Trabalho apresentado em 30th Annual Meeting of the European Society of Gene & Cell Therapy (ESGCT), Brussels, Belgium, 2023.
  15. Magda M Santana; D. Adão; De Luca, Pasqualino; R. Martins; Fernandes, Ana Rita; M. M. Pinto; Lopes, Sara M. ; Pereira de Almeida, Luis . Autor correspondente: Pereira de Almeida, Luis. "Neural induction and neuronal maturation of induced pluripotent stem cell is compromised in Machado-Joseph Disease lines". Trabalho apresentado em 30th Annual Meeting of the European Society of Gene & Cell Therapy (ESGCT), Brussels, Belgium, 2023.
  16. Silva, Ana Carolina; Henriques, Carina; Lobo, Diana Duarte; Fernandes, Ana Rita; Miguel M. Lopes; Pereira, Dina; Duarte, Sonia P.; et al. "Allele-specific silencing of mutant ATXN3 rescues motor deficits and neuropathology in a severely impaired mouse model of spinocerebellar ataxia type 3 (SCA3) upon intra-cisterna magna administration.". Trabalho apresentado em 30th Annual Meeting of the European Society of Gene & Cell Therapy (ESGCT), Brussels, Belgium, 2023.
  17. Silva, Ana Carolina; Henriques, Carina; Lobo, Diana Duarte; Pereira, Dina; Duarte, Sonia P.; Lopes, Sara M. ; Miguel M. Lopes; et al. "Investigating routes of administration and AAV serotypes for development of a gene-based therapy for spinocerebellar ataxia type 3 (SCA3)". Trabalho apresentado em 30th Annual Meeting of the European Society of Gene & Cell Therapy (ESGCT), Brussels, Belgium, 2023.
  18. Leandro, Kevin; Rufino-Ramos, David; Lopes, Sara M. ; Pasqua, C; Santos, P; Silva, Ana Carolina; Lobo, Diana Duarte; et al. Autor correspondente: Pereira de Almeida, Luis. "Extracellular vesicles-mediated delivery of CRISPR/Cas9 systems to treat Machado-Joseph Disease/Spinocerebellar Ataxia Type 3". Trabalho apresentado em 30th Annual Meeting of the European Society of Gene & Cell Therapy (ESGCT), Brussels, Belgium, 2023.
  19. Fernandes, Ana Rita; Adão, Diana; Lopes, Sara M. ; Henriques, Daniel; Pena, Frederico; Dias, Miguel; Magda M Santana; Pedro Perdigão; Pereira de Almeida, Luis . Autor correspondente: Pereira de Almeida, Luis. "Engineering isogenic neuronal models of ATXN3 knockout in Machado-Joseph Disease patient cells by CRISPR/Cas9". Trabalho apresentado em 30th Annual Meeting of the European Society of Gene & Cell Therapy (ESGCT), Brussels, Belgium, 2023.
  20. Lopes, Sara Monteiro; Miguel M. Lopes; Nobre, Rui Jorge; Vasconcelos-Ferreira, Ana; Pereira, Dina; Fernandes, Ana Rita; Barros, Maria Inês; et al. Autor correspondente: Pereira de Almeida, Luis. "Targeting the ATXN3 gene with CRISPR-Cas9 for the therapy of Machado-Joseph disease". Trabalho apresentado em 30th Annual Meeting of the European Society of Gene & Cell Therapy (ESGCT), Brussels, Belgium, 2023.
  21. De Luca, Pasqualino; Adão, Diana; Martins, Rita; Fernandes, Ana Rita; Pinto, Maria M; Lopes, Sara M. ; Magda M Santana; Pereira de Almeida, Luis . Autor correspondente: Pereira de Almeida, Luis. "Neuronal maturation of induced pluripotent stem cell is altered in Machado Joseph-Disease cell lines". Trabalho apresentado em ETRS & SPCE-TC joint meeting 2023, Coimbra, Portugal, 2023.
  22. Leandro, Kevin; Rufino-Ramos, David; Lopes, Sara M. ; Pasqua, Carlo; Santos, Paulo; Silva, Ana Carolina; Lobo, Diana Duarte; Pereira de Almeida, Luis. "Extracellular vesicles-mediated delivery of CRISPR/Cas9 systems to treat Machado-Joseph Disease". Trabalho apresentado em 2023 CAG Triplet Repeat Disorder -Gordon Research Conference, West Dover, Vermont, United States of America, 2023.
  23. Pedro Perdigão; Miguel Dias; Lopes, Sara M. ; Rita Fernandes; Frederico Pena; Miguel M. Lopes; Rui Nobre; Thomas Gaj; Luis Pereira de Almeida. "Engineering CRISPR-Based Editors for Treatment of Machado-Joseph Disease". Trabalho apresentado em American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting, 2023.
  24. Ribeiro, Rodrigo; Pereira, Dina; Reis, Tiago; Lopes, Sara M. ; Ferreira-Marques, Marisa; Fernandes, Rita; Gaspar, Laetitia S; et al. "The Circadian Clock is Disrupted in the YAC Machado-Joseph Disease Mouse Model". Trabalho apresentado em BEB Day 2023 - Doctoral Programme in Experimental Biology and Biomedicine (PDBEB) 17th symposium, 2023.
  25. Miguel M. Lopes; J. Paysan; J. Rino; Lopes, Sara M. ; Pereira de Almeida, Luis ; L. Cortes; R. J. Nobre. "Biodistribution analysis of AAV vectors in the brain using tissue clearing coupled to light-sheet microscopy". Trabalho apresentado em ESGCT (European Society for Gene and Cell Therapy) 29th Congress in collaboration with BSGCT, Edinburg, Scotland, 2022.
  26. Perdigão, P; Matos, Carlos A; Lopes, Sara; Fernandes, Ana Rita; Miguel M. Lopes; Conceição, André; Faro, Rosario; et al. "Modelling Machado-Joseph Disease in patient-derived isogenic lines by CRISPR/Cas9-mediated correction of ATXN3-CAG expansion". Trabalho apresentado em ESGCT 29th Annual Congress, European Society of Gene and Cell Therapy, Edinburgh, 2022, 2022.
  27. Leandro, Kevin; Rufino-Ramos, David; D'Amelio, T.; Salgueiro, Margarida A.; Lopes, Sara M. ; Pereira, Dina; Martins, M. I.; et al. Autor correspondente: Pereira de Almeida, Luis. "Extracellular vesicles-mediated delivery of CRISPR/Cas9 systems to treat Machado-Joseph Disease". Trabalho apresentado em 29th Congress of the European Society for Gene and Cell Therapy (ESGCT) in collaboration with BSGCT; Edinburgh, Scotland, United Kingdom, 2022.
  28. Silva, Ana Carolina; Lobo, Diana Duarte; Henriques, Carina; Martins, M. I.; Sara M. Lopes; Duarte, Sonia, P. ; Wagner, E. ; Nobre, Rui Jorge; Pereira de Almeida, Luis. "Silencing of mutant ATXN3 through antisense oligonucleotides rescues molecular and neuropathological features in Machado-Joseph disease mice". Trabalho apresentado em 29th Congress of the European Society for Gene and Cell Therapy (ESGCT) in collaboration with BSGCT; Edinburgh, Scotland, United Kingdom, 2022.
  29. Lopes, Sara M. ; Miguel M. Lopes; Rui J. Nobre; Clévio Nóbrega; Carlos A. Matos; Ana Vasconcelos-Ferreira; Dina Pereira; et al. Autor correspondente: Pereira de Almeida, L. "Engineered nucleases targeting the ATXN3 gene for the therapy of Machado-Joseph disease". Trabalho apresentado em 27th European Society for Animal Cell Technology Meeting (ESACT2022), Lisbon, Portugal, 2022.
  30. Ana Carolina Silva; Diana D. Lobo; Carina Henriques; Inês M. Martins; Sara M. Lopes* (D715-EE08-5DD9); Sónia P. Duarte; Elizabeth Wagner; Rui Jorge Nobre; Pereira de Almeida, Luis. "Antisense oligonucleotide mediated allele-specific silencing of mutant ATXN3 improves disease features in mouse models of Machado-Joseph disease". Trabalho apresentado em XVII Meeting of the Portuguese Society for Neuroscience (SPN2021), Coimbra, Portugal., 2021.
  31. Kevin Leandro; David Rufino-Ramos; Sara Lopes; Inês M. Martins; Diana Lobo; Manuela Paoletta; Rosário Faro; Pedro Perdigão; Pereira de Almeida, Luis. "Extracellular vesicles transient delivery of CRISPR/Cas9 systems to knock-out ataxin-3 expression". Trabalho apresentado em XVII Meeting of the Portuguese Society for Neuroscience (SPN2021), Coimbra, Portugal., 2021.
  32. Pedro Perdigão; Carlos Matos; Sara Lopes; Rita Fernandes; Miguel M. Lopes; Rosário Faro; Magda Santana; Rui Nobre; Pereira de Almeida, Luis. "Precise and scarless correction of ATXN3-CAG expansion by CRISPR/Cas9 for the generation of patient-derived MJD isogenic iPSC". Trabalho apresentado em XVII Meeting of the Portuguese Society for Neuroscience (SPN2021), Coimbra, Portugal., 2021.
  33. Leandro, Kevin; Rufino-Ramos, David; Lopes, Sara M. ; M. Martins, Inês; Lobo, Diana; Perdigão, Pedro; Faro, Rosário; Pereira de Almeida, Luis. "Extracellular vesicles-mediated delivery of CRISPR/Cas9 tools to treat Machado-Joseph Disease". Trabalho apresentado em 1st Meeting of the Portuguese Network on Extracellular Vesicles, 2021.
  34. Silva, Ana Carolina; Lobo, Diana Duarte; Henriques, Carina; Martins, Inês M.; Lopes, Sara M. ; Duarte, Sónia P; Wagner, Elizabeth; Nobre, Rui Jorge; Pereira de Almeida, Luis. "Allele-specific silencing of Machado-Joseph disease using antisense oligonucleotide therapeutics". Trabalho apresentado em 1st Symposium on Oligonucleotide Technologies and Therapeutics in Portugal (OTP2021), 2021.
  35. Miguel M. Lopes; Jacques Paysan; José Rino; Sara M. Lopes (D715-EE08-5DD9); Rui J. Nobre; Luísa Cortes; Pereira de Almeida, Luis. "Whole-Brain Analysis of Adeno-Associated Virus (AAV) Biodistribution with Single-Cell Resolution by Tissue Clearing and Light-Sheet Microscopy.". Trabalho apresentado em 1st Annual Meeting in Pharmaceutical Sciences. Coimbra, Portugal., 2019.
  36. Sara Lopes* (D715-EE08-5DD9); Carlos Matos*; André Conceição; Frederico Pena; Miguel M. Lopes; Rui Nobre; Clévio Nóbrega; et al. "CRISPR-Cas9 systems targeting ATXN3 as therapeutic approaches for Machado-Joseph Disease.". Trabalho apresentado em International Ataxia Research Conference (IARC 2019), Washington, DC. USA, 2019.
  37. Ana Ferreira; Inês Martins; Diana Lobo; Pereira, Dina; Miguel M. Lopes; Sara Lopes (D715-EE08-5DD9); Rosário Faro; et al. "Reinstating levels of dysregulated autophagy-associated transcripts alleviates neuropathology and motor impairments of mouse models of Machado-Joseph Disease.". Trabalho apresentado em International Ataxia Research Conference (IARC 2019). Washington, DC. USA., 2019.
  38. Sara Lopes* (D715-EE08-5DD9); Carlos Matos*; André Conceição; Frederico Pena; Miguel M. Lopes; Rui Nobre; Clévio Nóbrega; et al. "CRISPR-Cas9 systems targeting ATXN3 as therapeutic approaches for Machado-Joseph Disease.". Trabalho apresentado em 2019 International Machado-Joseph Research Disease Conference. Washington, DC. USA., 2019.
  39. Ana Ferreira; Inês Martins; Diana Lobo; Pereira, Dina; Miguel M. Lopes; Sara Lopes (D715-EE08-5DD9); Rosário Faro; et al. "Reinstating levels of dysregulated autophagy-associated transcripts alleviates neuropathology and motor impairments of mouse models of Machado-Joseph Disease.". Trabalho apresentado em 2019 International Machado-Joseph Research Disease Conference. Washington, DC. USA., 2019.
  40. Miguel M. Lopes; Jacques Paysan; José Rino; Sara M. Lopes (D715-EE08-5DD9); Rui J. Nobre; Luísa Cortes; Pereira de Almeida, Luis. "Whole-Brain Analysis of Adeno-Associated Virus (AAV) Biodistribution with Single-Cell Resolution by Tissue Clearing and Light-Sheet Microscopy.". Trabalho apresentado em EMBO | EMBL Symposium: Seeing Is Believing – Imaging the Molecular Processes of Life. Heidelberg, Germany., 2019.
  41. Carlos A. Matos; André Conceição; Sara Lopes (D715-EE08-5DD9); Pereira de Almeida, Luis . Autor correspondente: Pereira de Almeida, Luis. "CRISPR-Cas9 as a tool for silencing and correcting ATXN3, the gene causing Machado-Joseph disease.". Trabalho apresentado em XVI Meeting of the Portuguese Society for Neuroscience (SPN 2019). Lisbon, Portugal., 2019.
  42. Carlos A. Matos; André Conceição; Frederico Pena; Sara Lopes (D715-EE08-5DD9); Sónia Duarte; Catarina Miranda; Pereira de Almeida, Luis . Autor correspondente: Pereira de Almeida, Luis. "Transcriptional repression of mutant human ATXN3 using CRISPR interference mitigates the pathological phenotype of an in vivo Machado-Joseph disease model.". Trabalho apresentado em XVI Meeting of the Portuguese Society for Neuroscience (SPN 2019). Lisbon, Portugal., 2019.
  43. Ana Vasconcelos-Ferreira; Inês Morgado Martins; Diana Lobo; Pereira, Dina; Miguel M. Lopes; Sara Lopes (D715-EE08-5DD9); Rosário Faro; et al. "Reinstating levels of dysregulated autophagy-associated transcripts alleviates neuropathology and motor impairments of mouse models of Machado-Joseph disease.". Trabalho apresentado em XVI Meeting of the Portuguese Society for Neuroscience (SPN 2019). Lisbon, Portugal, 2019.
  44. Matos, C.A.; Pena, F.; Conceição, A.; Lopes, Sara M. ; Duarte, S.; Miranda, C.; Pereira de Almeida, Luis. "CRISPR-Cas9-mediated pre-transcriptional silencing of mutant ATXN3 decreases motor impairments of an in vivo Machado-Joseph disease model.". Trabalho apresentado em 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), Washington, DC, USA., 2019.
  45. Lopes, S. M. (D715-EE08-5DD9); Nobre, R.; Nóbrega, C.; Lopes, M.M; Matos, C.A.; Sanjana, N.; Hsu, P.; et al. "TALEN and CRISPR gene-editing for treatment of Machado-Joseph disease.". Trabalho apresentado em 2nd International Ataxia Research Conference (IARC 2017). Pisa, Italy., 2017.
  46. Santana, M.M.*; Lopes, S. M.* (D715-EE08-5DD9); Onofre, I.; Álvaro, A.R.; Di Donato, R.; Pereira de Almeida, Luis ; *Equally contributed. "Generation of Machado-Joseph disease induced pluripotent cell lines and isogenic controls, using the CRISPR/Cas9 technology.". Trabalho apresentado em 2nd International Ataxia Research Conference (IARC 2017). Pisa, Italy., 2017.
  47. Matos, C.A.; Lopes, S. (D715-EE08-5DD9); Pereira de Almeida, Luis. "CRISPR-Cas9 as a tool for Machado-Joseph disease treatment and animal model generation.". Trabalho apresentado em EMBO Practical Course on Mouse Genome Engineering. Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG), Dresden, Germany., 2017.
  48. Onofre, Isabel; Mendonça, Nuno; Lopes, Sara (D715-EE08-5DD9); Nobre, Rui; Barbosa, Joana; Carreira, Isabel M; Carvalho, Lina; et al. "Characterization of a human Machado-Joseph Disease neuronal cell model derived from induced pluripotent stem cells.". Trabalho apresentado em 9th Annual meeting of the Portuguese Society for Stem Cells and Cell Therapies. Braga, Portugal., 2015.
  49. Onofre, Isabel; Mendonça, Nuno; Lopes, Sara (D715-EE08-5DD9); Nobre, Rui; Barbosa, Joana; Carreira, Isabel M.; Carvalho, Lina; et al. "Characterization of a human Machado-Joseph disease neuronal cell model derived from induced pluripotent stem cells.". Trabalho apresentado em 12th International Society for Stem Cell Research (lSSCR 2015) Annual Meeting. Stockholm, Sweden., 2015.
  50. Sara Lopes (D715-EE08-5DD9); Rui Nobre; Clévio Nobrega; Neville Sanjana; Le Cong; Patrick Hsu; Fei Ann Ran; Feng Zhang; Pereira de Almeida, Luis. "Gene editing strategies towards Machado Joseph disease.". Trabalho apresentado em EMBO workshop: Modern DNA concepts and tools for safe gene transfer and modification. Institut de Biologie Génétique et Bio-Informatique (IBGBI), Evry-Val d'Essonne, France., 2015.
  51. Santana, Magda M; Nobrega, Clévio; Nobre, Rui Jorge; Miranda, Catarina Oliveira; Mendonça, Liliana; Sousa-Ferreira, Ligia; Simões, Ana Teresa; et al. "Gene therapy approaches to investigate pathogenesis and disease modifying strategies for neurodegenerative diseases". Trabalho apresentado em Showcasing Portuguese Pharma Science:Advances in Discovery, Development and Manufacturing. Hovione and MIT Portugal Pharma Science Symposium, 2014.
Pré-impressão
  1. Rodrigo F.N. Ribeiro; Dina Pereira; Lopes, Sara M. ; Tiago Reis; Patrick Silva; Diana D. Lobo; Laetitia S. Gaspar; et al. "Circadian Rhythms are Disrupted in Patients and Preclinical Models of Machado-Joseph Disease". 2025. https://doi.org/10.1101/2025.01.03.631212.
    10.1101/2025.01.03.631212
  2. Lopes, Sara M. ; Lopes, Miguel Monteiro; Oliveira, Daniela; Santana, Magda Matos; Fernandes, Ana Rita; Vasconcelos-Ferreira, Ana; Pereira, Dina; et al. "Gene Editing for ATXN3 Inactivation in Machado-Joseph disease: CRISPR-Cas9 as a Therapeutic Alternative to TALEN-Induced Toxicity". 2025. https://doi.org/10.1101/2025.02.14.637261.
    10.1101/2025.02.14.637261
  3. Pereira, Dina; Cunha-Santos, Janete; Vasconcelos-Ferreira, Ana; Duarte-Neves, Joana; Onofre, Isabel; Carmona, Vítor; Aveleira, Célia A; et al. "Nuclear aging in polyglutamine-induced neurodegeneration". 2023. https://doi.org/10.1101/2023.06.09.544056.
    10.1101/2023.06.09.544056
Resumo em conferência
  1. P. De Luca; Lopes, Sara M. ; Pereira, Dina; L.S. Gaspar; B. Marques; P. Perdigão; A. Melo; et al. "Optimizing in vitro transcription methods for enhanced mRNA-based therapeutics.". Trabalho apresentado em 31st Annual Congress of the European Society for Gene and Cell Therapy (ESGCT), Rome, 2025.
    Publicado • 10.1089/hum.2024.63331.oab
  2. L. Gaspar; B. Marques; Pereira, Dina; P. De Luca; P. Perdigão; Lopes, Sara M. ; R. Perfeito; et al. "Maximizing Yield and Functionality in saRNA Production: A Comparative Study of Commercial Kits and In Vitro Transcription Conditions". Trabalho apresentado em 31st Annual Congress of the European Society for Gene and Cell Therapy (ESGCT), Rome, 2025.
    Publicado • 10.1089/hum.2024.63331.oab
  3. Pereira, Dina; A.S. Valdeira; L.S. Gaspar; P. De Luca; P. Perdigão; Lopes, Sara M. ; F.S.Silva; et al. "A comparative analysis of commercial kits for enhanced circular mRNA production: yield, profile, and in vitro assessment". Trabalho apresentado em 31st Annual Congress of the European Society for Gene and Cell Therapy (ESGCT), Rome, 2025.
    Publicado • 10.1089/hum.2024.63331.oab
  4. C. Miranda; R. Perfeito; S.P. Duarte; C. Paulo; M.T. Rodrigues; L.S. Gaspar; Pereira, Dina; et al. "Comparative Analysis of Transfection Kits for Linear, Self-Amplifying, and Circular RNA". Trabalho apresentado em 31st Annual Congress of the European Society for Gene and Cell Therapy (ESGCT), Rome, 2025.
    Publicado • 10.1089/hum.2024.63331.oab
  5. A.C. Silva; C. Henriques; Diana D. Lobo; A.R. Fernandes; Miguel M. Lopes; K. Leandro; Pereira, Dina; et al. "Intra-cisterna magna administration of allele-specific AAV-based therapy alleviates neuropathology and motor deficits in Spinocerebellar Ataxia Type 3.". Trabalho apresentado em 31st Annual Congress of the European Society for Gene and Cell Therapy (ESGCT), Rome, 2025.
    Publicado • 10.1089/hum.2024.63331.oab
  6. Silva, A.C.; Henriques, C; Lobo, Diana D.; Fernandes, A.R; Miguel M. Lopes; Pereira, Dina; Duarte, S.; et al. "Allele-Specific Silencing of Mutant ATXN3 Mitigates Motor Deficits and Neuropathology in a Severely Impaired Mouse Model of Spinocerebellar Ataxia Type 3 (SCA3)". Trabalho apresentado em 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), Baltimore, 2024.
    Publicado • 10.1016/j.ymthe.2024.04.020
  7. Lopes, Sara M. ; Miguel M. Lopes; Nobre, Rui Jorge; Vasconcelos-Ferreira, Ana; Pereira, Dina; Fernandes, Ana Rita; Barros, Inês; et al. Autor correspondente: Pereira de Almeida, Luis. "Targeting the ATXN3 gene with CRISPR-Cas9 for the therapy of Machado-Joseph disease". Trabalho apresentado em 30th Annual Meeting of the European Society of Gene & Cell Therapy (ESGCT), Brussels, 2024.
    Publicado
  8. A.R. Fernandes; D. Adão; Lopes, Sara M. ; D. Henriques; F. Pena; M. Dias; M. M. Santana; P. Perdigão; L. P. Almeida. "Engineering isogenic neuronal models of ATXN3 knockout in Machado-Joseph Disease patient cells by CRISPR/Cas9". Trabalho apresentado em 30th Annual Congress of the European Society for Gene and Cell Therapy (ESGCT), Brussels, 2024.
    Publicado • 10.1089/hum.2023.29258.abstracts
  9. K. Leandro; D. Rufino-Ramos; Lopes, Sara M. ; C. Pasqua; P. Santos; C. Silva; D. Lobo; et al. "Extracellular vesicles-mediated delivery of CRISPR/Cas9 systems to treat Machado-Joseph Disease/Spinocerebellar Ataxia Type 3". Trabalho apresentado em 30th Annual Congress of the European Society for Gene and Cell Therapy (ESGCT), Brussels, 2024.
    Publicado • 10.1089/hum.2023.29258.abstracts
  10. M. M. Santana; D. Adão; P. De Luca; R. Martins; A.R. Fernandes; M. M. Pinto; Lopes, Sara M. ; L.P. de Almeida. "Neural induction and neuronal maturation of induced pluripotent stem cell is compromised in Machado-Joseph Disease lines". Trabalho apresentado em 30th Annual Congress of the European Society for Gene and Cell Therapy (ESGCT), Brussels, 2024.
    Publicado • 10.1089/hum.2023.29258.abstracts
  11. I. Barros; D. Gonzaga; D. D. Lobo; Lopes, Sara M. ; I. Martins; A. Silva; L. P. Almeida; C. O. Miranda. "The guardians of balance: mesenchymal stem cells as a promising strategy to restore blood-brain barrier integrity in spinocerebellar ataxia type 3". Trabalho apresentado em 30th Annual Congress of the European Society for Gene and Cell Therapy (ESGCT), Brussels, 2024.
    Publicado • 10.1089/hum.2023.29258.abstracts
  12. C. Silva; C. Henriques; D. D. Lobo; A.R. Fernandes; Miguel M. Lopes; Pereira, Dina; S.P. Duarte; et al. "Allele-specific silencing of mutant ATXN3 rescues motor deficits and neuropathology in a severely impaired mouse model of spinocerebellar ataxia type 3 (SCA3) upon intra-cisterna magna administration". Trabalho apresentado em 30th Annual Congress of the European Society for Gene and Cell Therapy (ESGCT), Brussels, 2024.
    Publicado • 10.1089/hum.2023.29258.abstracts
  13. A.C. Silva; C. Henriques; D. D. Lobo; Pereira, Dina; S.P. Duarte; Lopes, Sara M. ; Miguel M. Lopes; et al. "Investigating routes of administration and AAV serotypes for development of a gene-based therapy for spinocerebellar ataxia type 3 (SCA3)". Trabalho apresentado em 30th Annual Congress of the European Society for Gene and Cell Therapy (ESGCT), Brussels, 2024.
    Publicado • 10.1089/hum.2023.29258.abstracts
  14. D. D. Lobo; L. Quintino; A.C. Silva; C. Henriques; R. Ribeiro; Lopes, Sara M. ; P. Perdigão; et al. "CRISPR activation as a therapeutic tool for Spinocerebellar ataxia type 3 (SCA3)". Trabalho apresentado em 30th Annual Congress of the European Society for Gene and Cell Therapy (ESGCT), Brussels, 2024.
    Publicado • 10.1089/hum.2023.29258.abstracts
  15. Perdigao, P.; Dias, M.; Lopes, Sara M. ; Fernandes, R.; Pena, F.; Miguel M. Lopes; Nobre, R.; Gaj, T.; de Almeida, L.P.. "Engineering CRISPR-Based Editors for Treatment of Machado-Joseph Disease". Trabalho apresentado em 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), Los Angeles, 2023.
    Publicado • 10.1016/j.ymthe.2023.04.017
  16. Miguel M. Lopes; Jacques Paysan; José Rino; Lopes, Sara M. ; Luís P. Almeida; Luisa Cortes; Rui J. Nobre. "Biodistribution analysis of AAV vectors in the brain using tissue clearing coupled to light-sheet microscopy". Trabalho apresentado em 29th Congress of the European Society for Gene and Cell Therapy (ESGCT) in collaboration with BSGCT; Edinburgh, Scotland, United Kingdom, Edinburgh, 2022.
    Publicado • 10.1089/hum.2022.29225.abstracts
  17. Pedro Perdigão; Carlos Matos; Lopes, Sara M. ; Rita Fernandes; Miguel M. Lopes; Andre Conceicao; Rosário Faro; et al. "Modelling Machado-Joseph Disease in patient-derived isogenic lines by CRISPR/Cas9-mediated correction of ATXN3-CAG expansion". Trabalho apresentado em 29th Congress of the European Society for Gene and Cell Therapy (ESGCT) in collaboration with BSGCT; Edinburgh, Scotland, United Kingdom, Edinburgh, 2022.
    Publicado • 10.1089/hum.2022.29225.abstracts
  18. K. Leandro; D. Rufino-Ramos; T. D'Amelio; A. Margarida Salgueiro; Lopes, Sara M. ; Pereira, Dina; I. M. Martins; et al. "Extracellular vesicles-mediated delivery of CRISPR/Cas9 systems to treat Machado-Joseph Disease". Trabalho apresentado em 29th Congress of the European Society for Gene and Cell Therapy (ESGCT) in collaboration with BSGCT; Edinburgh, Scotland, United Kingdom, Edinburgh, 2022.
    Publicado • 10.1089/hum.2022.29225.abstracts
  19. A.C. Silva; D. D. Lobo; C. Henriques; I. M. Martins; Lopes, Sara M. ; S.P. Duarte; Wagner, E. ; Nobre, Rui; L., Pereira de Almeida. "Silencing of mutant ATXN3 through antisense oligonucleotides rescues molecular and neuropathological features in Machado-Joseph disease mice". Trabalho apresentado em 29th Congress of the European Society for Gene and Cell Therapy (ESGCT) in collaboration with BSGCT; Edinburgh, Scotland, United Kingdom, Edinburgh, 2022.
    Publicado • 10.1089/hum.2022.29225.abstracts
  20. Lopes, Sara M. ; Miguel M. Lopes; Rui Nobre; Clévio Nóbrega; Matos, Carlos A; Ana Vasconcelos-Ferreira; Neville Sanjana; et al. Autor correspondente: Pereira de Almeida, Luis. "Permanent inactivation of the ATXN3 gene: a possible therapeutic approach for Machado-Joseph disease". Trabalho apresentado em 24th Annual Meeting of the Portuguese Society of Human Genetics (SPGH), Virtual Conference, 2021.
    Publicado
  21. Carlos A. Matos; Frederico Pena; Andre Conceicao; Lopes, Sara M. ; Sónia Duarte; Catarina Miranda; Luis Pereira de Almeida. "CRISPR-Cas9-Mediated Pre-Transcriptional Silencing of Mutant ATXN3 Decreases Motor Impairments of an In Vivo Machado-Joseph Disease Model. MOLECULAR THERAPY (2019) 27 (4): 120-121". Trabalho apresentado em 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), Washington, DC, USA, 2019, 2019.
    Publicado
Tese / Dissertação
  1. "Gene editing technologies to Machado-Joseph disease". Doutoramento, Universidade de Coimbra Instituto de Investigação Interdisciplinar, 2021. https://estudogeral.uc.pt/handle/10316/105165.

Artística / Interpretação

Obra teatral
  1. Marionet theatre company. 2016. O Ponto que nos une.

Propriedade Intelectual

Pedido provisório de patente
  1. 2025. "CRISPR-Cas9 based tools: Potential novel therapeutic approaches for Machado-Joseph disease".
  2. 2020. "Oligonucleotide primers for the characterization of the CAG tract and measurement of mutant mRNA in the context of polyglutamine disorders".
Atividades

Apresentação oral de trabalho

Título da apresentação Nome do evento
Anfitrião (Local do evento)
2024/11 Allele-specific silencing of mutant ataxin-3 via single administration of AAV9 vectors mitigates neuropathology and motor deficits in Spinocerebellar Ataxia Type 3 2024 International Congress for Ataxia Research (ICAR2024)
(London, Reino Unido)
2024/11 CRISPR-Cas9-mediated ATXN3 gene inactivation as a potential therapeutic approach for Machado-Joseph disease 2024 International Congress for Ataxia Research (ICAR2024)
(London, Reino Unido)
2024/02/09 Targeted silencing via AAV9 polycistronic microRNA therapy rescues SCA3 molecular, neuropathological and motor deficits 54th Meeting of the Portuguese Society of Pharmacology (SPF2024)
(Lisbon, Portugal)
2024/02 Mesenchymal Stromal Cell Therapeutic Potential to Restore Neurovascular Integrity in Spinocerebellar Ataxia Type 3 54th Meeting of the Portuguese Society of Pharmacology (SPF2024)
(Lisbon, Portugal)
2023/06/15 Extracellular vesicles-mediated delivery of CRISPR/Cas9 systems to treat Machado-Joseph Disease 2023 CAG Triplet Repeat Disorder -Gordon Research Conference
(West Dover, Vermont, Estados Unidos)
2023/02 Investigating the clock components and circadian activity in the YAC-MJD mouse model Meeting of the Portuguese Society of Pharmacology (SPF2023)
(Coimbra, Portugal)
2023/02 Extracellular vesicles delivery of CRISPR-Cas9 RNPs for therapeutic gene editing in Spinocerebellar Ataxia Type 3 54th Meeting of the Portuguese Society of Pharmacology (SPF2024)
(Lisbon, Portugal)
2022/06/27 Engineered nucleases targeting the ATXN3 gene for the therapy of Machado-Joseph disease (Flash Talk Presentation) 27th European Society for Animal Cell Technology Meeting (ESACT2022)
(Lisbon, Portugal)
2022/02/10 Extracellular vesicles-mediated delivery of CRISPR/Cas9 systems for therapeutic genome editing Meeting of the Portuguese Society of Pharmacology (SPF2022)
(Porto, Portugal)
2022/02/10 Correction of ATXN3-CAG expansion in MJD patient-derived IPSC by CRISPR/Cas9 homology directed repair Meeting of the Portuguese Society of Pharmacology (SPF2022)
(Porto, Portugal)
2022 Modelling Machado-Joseph Disease in patient-derived isogenic lines by CRISPR/Cas9 homology directed repair 26th Annual Portuguese Society of Human Genetics Meeting (SPGH2022)
(Coimbra, Portugal)
2021/02/19 Phenotypic characterization of a relevant model of Machado-Joseph disease: The YAC-MJD mouse model. Meeting of the Portuguese Society of Pharmacology (SPF2021)
(Virtual Meeting, Portugal)
2021/02/19 Phenotypic characterization of neuronal cultures derived from Machado-Joseph disease induced pluripotent stem cells. Meeting of the Portuguese Society of Pharmacology (SPF2021)
(Virtual Meeting, Portugal)
2021/02/18 Allele-specific silencing of Machado-Joseph disease using antisense oligonucleotide therapeutics Meeting of the Portuguese Society of Pharmacology (SPF2021)
(Virtual Meeting, Portugal)
2020/11/25 Whole-Brain Biodistribution Analysis of Adeno-Associated Virus (AAV) with Single-Cell Resolution by Tissue Clearing and Light-Sheet Microscopy Early Career European Microscopy Congress 2020
(Virtual Meeting, Reino Unido)
2020/11/20 Permanent Inactivation of the ATXN3 Gene: A Possible Therapeutic Approach for Machado-Joseph Disease 24th Annual meeting of the Portuguese Society of Human Genetics (SPGH 2020)
(Virtual meeting, Portugal)
2020/02/07 CRISPR-mediated silencing of mutant ataxin-3 ameliorates motor symptoms of a Machado-Joseph disease model in vivo. XLX Meeting of the Portuguese Society of Pharmacology (SPF2020)
(Coimbra, Portugal)
2019/11/15 Reinstating levels of dysregulated autophagy-associated transcripts alleviates neuropathology and motor impairments of mouse models of Machado-Joseph Disease. International Ataxia Research Conference (IARC 2019).
(Washington, DC. , Estados Unidos)
2019/11/14 CRISPR-Cas9 systems targeting ATXN3 as therapeutic approaches for Machado-Joseph Disease. Flash Talk Presentation. International Ataxia Research Conference (IARC 2019).
(Washington, DC, Estados Unidos)
2019/11/13 CRISPR-Cas9 systems targeting ATXN3 as therapeutic approaches for Machado-Joseph Disease. 2019 International Machado-Joseph Research Disease Conference.
(Washington, DC., Estados Unidos)
2019/11/12 Reinstating levels of dysregulated autophagy-associated transcripts alleviates neuropathology and motor impairments of mouse models of Machado-Joseph Disease. 2019 International Machado-Joseph Research Disease Conference.
(Washington, DC., Estados Unidos)
2019/11/07 Whole-Brain Analysis of Adeno-Associated Virus (AAV) Biodistribution with Single-Cell Resolution by Tissue Clearing and Light-Sheet Microscopy. 2019 Spanish & Portuguese Advanced Optical Microscopy Meeting (SPAOM 2019).
(Coimbra, Portugal)
2019/11/07 A New Clearing Method for Whole-Brain Imaging with Single-Cell Resolution. 2019 Spanish & Portuguese Advanced Optical Microscopy Meeting 2019 (SPAOM 2019).
(Coimbra, Portugal)
2019/10/09 Whole-Brain Analysis of Adeno-Associated Virus (AAV) Biodistribution with Single-Cell Resolution by Tissue Clearing and Light-Sheet Microscopy. Flash Talk Presentation. EMBO | EMBL Symposium: Seeing Is Believing – Imaging the Molecular Processes of Life.
(Heidelberg, Alemanha)
2019/05/31 Permanent inactivation of the ATXN3 gene: A possible therapeutic approach for Machado-Joseph disease. XVI Meeting of the Portuguese Society for Neuroscience (SPN 2019).
(Lisbon, Portugal)
2019/05/22 CRISPR interference-mediated silencing of mutant ATXN3 decreases motor impairments of an in vivo Machado-Joseph disease model. 53rd Annual Scientific Meeting of the European Society for Clinical Investigation (ESCI).
(Coimbra, Portugal)
2018/05 Non-invasive brain delivery of hybrid extracellular vesicles for therapy of Machado-Joseph Disease (MJD). Annual Meeting ISEV2018.
(Barcelona, Espanha)
2018/03/03 Tailoring gene editing strategies for the treatment of Machado-Joseph disease. Portuguese Society of Movement Disorders (SPDMov 2018).
(Curia, Portugal)
2018/02/17 Hybrid vesicles: a promising therapeutic approach for MJD and other neurodegenerative diseases. 1st Meeting on Vesicular Biology.
(Coimbra, Portugal)
2018/02/07 Protocol for the characterization of CAG tract and flanking polymorphisms in polyQ disorders: impact on the diagnosis and in the development of gene-based therapies. XLVIII Portuguese Society of Pharmacology Annual Meeting (SPF 2018).
(Lisbon, Portugal)
2018/02/07 Generation of a Machado-Joseph disease isogenic control induced pluripotent stem cell line. XLVIII Portuguese Society of Pharmacology Annual Meeting (SPF 2018).
(Lisbon, Portugal)
2018/02/07 AAV-Based tools for the development of cellular and animal models of Machado-Joseph disease. XLVIII Portuguese Society of Pharmacology Annual Meeting (SPF 2018).
(Lisbon, Portugal)
2018/02/07 CRISPR-Cas9-mediated pre-transcriptional silencing of mutant ataxin-3. XLVIII Portuguese Society of Pharmacology Annual Meeting (SPF 2018).
(Lisbon, Portugal)
2018/02/06 Reinstating levels of dysregulated autophagy-associated transcripts alleviates neuropathology and motor impairments of mouse models of Machado-Joseph disease. XLVIII Portuguese Society of Pharmacology Annual Meeting (SPF 2018).
(Lisbon, Portugal)
2018/01/15 Exosomes: tiny vesicles with great potential for MJD treatment. XII Spanish-Portuguese Conference on Controlled Drug Delivery.
(Coimbra, Portugal)
2017/09/30 TALEN and CRISPR gene-editing for treatment of Machado-Joseph disease. 2nd International Ataxia Research Conference (IARC 2017).
(Pisa, Itália)
2017/02/03 Gene editing strategies for Machado-Joseph disease. XLVII Portuguese Society of Pharmacology Annual Meeting (SPF 2017).
(Coimbra, Portugal)
2017/02/03 Pre-transcriptional silencing of ataxin-3 using a CRISPR-Cas9-derived system. XLVII Portuguese Society of Pharmacology Annual Meeting (SPF 2017).
(Coimbra, Portugal)

Orientação

Título / Tema
Papel desempenhado 		Curso (Tipo)
Instituição / Organização
2024/09/01 - 2025/08/31 Duchenne Muscular Dystrophy: Literature Review, Pilot Study on Prevalence in the Azores, and Proposal for a novel therapeutic approach using the CRISPR-Cas9 system
Coorientador
 Mestrado em Ciências Biomédicas (Mestrado)
Universidade dos Açores, Portugal
2025/02 - 2025/06 Gene editing strategies for the treatment of diseases – from the bench to the community
Coorientador
 Projecto em Biologia Aplicada II (Licenciatura/Bacharelato)
Universidade de Coimbra, Portugal

Organização de evento

Nome do evento
Tipo de evento (Tipo de participação) 		Instituição / Organização
2013/12/18 - 2013/12/20 XI Annual CNC Meeting (2013/12/18 - 2013/12/20)
Encontro (Membro da Comissão Organizadora)
 Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
2012/06/02 - 2012/06/02 1st BEB Symposium "Science Dreams, challenges arise" (2012/06/02 - 2012/06/02)
Simpósio (Membro da Comissão Organizadora)
 Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal

Participação em evento

Descrição da atividade
Tipo de evento 		Nome do evento
Instituição / Organização
2024/09/27 - Atual European Researchers' Night 2024
2020/04/22 - 2020/06/30 Bootcamp in the framework of the innovation programme in neuroscience - Building Tomorrow Together
Outro
 Building Tomorrow Together
Roche Farmaceutica Quimica Lda, Portugal
2016/11/18 - 2016/11/19 1st International Symposium - Brain Without Borders, held in Coimbra, Portugal. This event offered the opportunity to promote discussion on fundamental and translational research in stem cell biology applied to the Central Nervous System. A group of leading researchers from all over the world presented and discussed their work, sharing recent findings on 2D and 3D in vitro neuronal models, stem cell transplantation, in vivo gene therapy and neural tissue engineering.
Simpósio
 Brain Without Borders
Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
2016/06/27 - 2016/07/01 Interdisciplinary educational program adressing concepts on how to offer "support for the aging society and create knowledge to deliver innovation and business." The course was part of the EIT Health Campus programme
Outro
 Entrepreneurial Introductory Translational Research (EITR)
Exzellenzcluster CECAD in der Universität zu Köln, Alemanha
2016/03/17 - 2016/03/20 10th World Congress on Controversies in Neurology (CONy), Lisbon, Portugal. This event offered the opportunity to promote discussion on the molecular mechanisms of Machado-Joseph disease (MJD) and associated clinical features, discussing key considerations related with the translation from pre-clinical studies to clinical trials.
Congresso
 10th World Congress on Controversies in Neurology (CONy)
2015/12 - 2015/12 Workshop on Applications of CRISPR to Genetically Tractable Organisms
Oficina (workshop)
Fundação Champalimaud, Portugal
2014 - 2014 Laboratory animal science category B Course, under FELASA guidelines. Course focused on the training of scientists to manipulate laboratory animals.
Outro
 Training in Laboratory Animal Science
Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
2012/10 - 2012/11/03 Bloodborne pathogen for researchers' course
Outro
Broad Institute, Estados Unidos
2012/10 - 2012/10/24 Managing hazardous waste course
Outro
Broad Institute, Estados Unidos

Júri de grau académico

Tema
Tipo de participação 		Nome do candidato (Tipo de grau)
Instituição / Organização
2024/10/30 BSc monograph, Integrated Master in Pharmaceutical Sciences - Title: Tecnologia CRISPR-Cas9 como potencial cura para a infeção por HIV-1 e seus desafios
Arguente principal
 Diana Antunes dos Santos (Mestrado)
Universidade de Coimbra Faculdade de Farmácia, Portugal
2024/09/24 BSc monograph, Integrated Master in Pharmaceutical Sciences - Title: Ketogenic Diet as Therapy of Neurodegenerative Diseases
Arguente principal
 Daniela Carolina Magro Dias Jorge Trino (Mestrado)
Universidade de Coimbra Faculdade de Farmácia, Portugal
2022/09/21 Evaluation of patients with neurological diseases due to nucleotide repeat expansions
Arguente principal
 Madalena Maria Petronilo Marques (Mestrado)
Universidade de Coimbra Faculdade de Farmácia, Portugal
2021/12/14 Impacto dos Polimorfismos de Nucleótido Único em Genes Associados a Doenças de Poliglutaminas para o Desenvolvimento de Terapias Génicas
Arguente principal
 Sara Alexandra Nascimento Costa e Pires Martins (Mestrado)
Universidade de Coimbra Faculdade de Farmácia, Portugal

Curso / Disciplina lecionado

Disciplina Curso (Tipo) Instituição / Organização
2024/09/01 - 2025/08/31 Cellular and Molecular Biology (Invited Assistant Professor) Biologia Celular e Biologia Molecular (Mestrado integrado) Universidade de Coimbra Faculdade de Farmácia, Portugal
2023/04/14 - 2023/04/14 Gene repair and models of disease Master in Pharmaceutical Biotechnology (Mestrado) Universidade de Coimbra Faculdade de Farmácia, Portugal
2023/03/03 - 2023/03/03 Gene editing in brain diseases Master in Molecular and Translational Neuroscience (Mestrado) Universidade de Coimbra Faculdade de Medicina, Portugal
2022/04 - 2022/08 Molecular Biology (Invited Assistant Professor) Biologia Molecular (Mestrado integrado) Universidade de Coimbra Faculdade de Farmácia, Portugal
2022/05/27 - 2022/05/27 Therapies based on gene editing: Potentialities and limitations Integrated Master's degree in Medicine, Interdisciplinary Seminar of Applied Molecular Biology and Fundamentals of Neuroscience (Mestrado integrado) Universidade dos Açores, Portugal
2022/05/12 - 2022/05/12 Therapies based on gene editing: Potentialities and limitations Interdisciplinary Seminar of Applied Molecular Biology and Fundamentals of Neuroscience (Mestrado integrado) Universidade de Coimbra Faculdade de Medicina, Portugal
2022/04/12 - 2022/04/12 Therapies based on gene editing: Potentialities and limitations Advanced Therapies Course, Doctoral Programme in Experimental Biology and Biomedicine (Doutoramento) Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
2021/04/21 - 2021/04/21 Therapies based on gene editing: Potentialities and limitations Advanced Therapies course, Doctoral Programme in Experimental Biology and Biomedicine (Doutoramento) Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
2021/03/16 - 2021/03/16 Gene Editing Genética Molecular Humana, Mestrado Análises Clínicas (Mestrado) Universidade de Coimbra Faculdade de Farmácia, Portugal
2021/03/15 - 2021/03/15 Genotyping, Haplotypes and CAGs Genética Molecular Humana, Mestrado Análises Clínicas (Mestrado) Universidade de Coimbra Faculdade de Farmácia, Portugal
2020/05/02 - 2020/05/02 Gene repair and models of disease Terapêutica Molecular e Engenharia de Tecidos, Mestrado de Biotecnologia Farmacêutica (Mestrado) Universidade de Coimbra Faculdade de Farmácia, Portugal
2019/04/22 - 2019/04/22 Gene editing strategies in gene therapy Advanced Therapies course, Doctoral Programme in Experimental Biology and Biomedicine (Doutoramento) Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
2019/03/30 - 2019/03/30 Gene repair and models of disease Terapêutica Molecular e Engenharia de Tecidos, Mestrado de Biotecnologia Farmacêutica (Mestrado) Universidade de Coimbra Faculdade de Farmácia, Portugal
2018/05/08 - 2018/05/08 Nuclease-based genome editing technologies Advanced Therapies course, : Doctoral Programme in Experimental Biology and Biomedicine (Doutoramento) Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
2018/04/14 - 2018/04/14 Gene repair and models of disease Terapêutica Molecular e Engenharia de Tecidos, Mestrado de Biotecnologia Farmacêutica (Mestrado) Universidade de Coimbra Faculdade de Farmácia, Portugal
2017/06/16 - 2017/06/16 Therapies based on gene editing using CRISPR and TALEN: Potentialities and limitations Mestrado de Farmacologia Aplicada (Mestrado) Universidade de Coimbra Faculdade de Farmácia, Portugal
2017/03/25 - 2017/03/25 Gene repair and disease models Terapêutica Molecular e Engenharia de Tecidos, Mestrado de Biotecnologia Farmacêutica (Mestrado) Universidade de Coimbra Faculdade de Farmácia, Portugal
2017/03/16 - 2017/03/16 Aula Prática de Tecnologia Farmacêutica I Tecnologia Farmacêutica I (Mestrado integrado) Universidade de Coimbra Faculdade de Farmácia, Portugal
2016/06/25 - 2016/06/25 Gene edition: TALENs and CRISPR Mestrado de Farmacologia Aplicada Universidade de Coimbra Faculdade de Farmácia, Portugal
2016/06/16 - 2016/06/16 Gene editing strategies in gene therapy Advanced Therapies course, Doctoral Programme in Experimental Biology and Biomedicine (Doutoramento) Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal

Membro de associação

Nome da associação Tipo de participação
2023/12 - Atual Ataxia Global Initiative (AGI)
2023/06 - Atual European Society for Gene and Cell Therapy (ESGCT)
2019/02 - Atual Sociedade Portuguesa de Neurociências
2012/09/20 - Atual Ordem dos Farmacêuticos

Revisão ad hoc de artigos em revista

Nome da revista (ISSN) Editora
2023 - 2024 Molecular Therapy
2023 - 2023 Human Molecular Genetics

Tutoria

Tópico Nome do aluno
2022/12 - 2023/06 MJDedit - Systems of gene editing for the ATXN3 gene Maria Adelaide Catarino Casquinha
2020/12 - 2022/08 Research fellow in the context of a project funded by a Pharmaceutical company Ana Daniela Oliveira
2019/09 - 2020/12 Phenotypic characterization of cellular and animal models of Machado-Joseph disease Ana Daniela Oliveira
Distinções

Prémio

2020 First prize of the innovation programme in neuroscience: Building Tomorrow Together (Roche initiative) with the project ExoTreat
Roche Farmaceutica Quimica Lda, Portugal
2020 Best Basic Research award for the work presented at the Portuguese Society of Human Genetics
Sociedade Portuguesa de Genética Humana (SPGH), Portugal
2018 Best work in basic science presented at the Portuguese Society of Movement Disorders
Sociedade Portuguesa das doenças do Movimento (SPDMov), Portugal
2017 EIT Health PhD transition Fellowship (3rd prize) for the project "ExoEditor - A combined therapeutic strategy for Machado-Joseph disease"
EIT Health, Alemanha

Outra distinção

2025 Travel Award to attend the Rare Disease Research Conference 2025, Dublin, Ireland
The Rare Disease Clinical Trial Network, Irlanda
2019 Travel bursary to attend the MJD Satellite Conference in Washington DC, USA.
MJD Foundation, Austrália
2017 Young Investigator Bursary to attend the IARC2017 congress
Ataxia UK, Reino Unido
2016 Travel Award for the CECAD Short Course on Entrepreneurial Introductory Translational Research (EITR)
Exzellenzcluster CECAD in der Universität zu Köln, Alemanha
2011 Individual 4-year PhD Fellowship (Ref. SFRH/BD/51673/2011).
Associação para a Inovação e Desenvolvimento da FCT, Portugal